Ultragenyx Pharma (RARE) Misses Q1 EPS by 79c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Ultragenyx Pharma (RARE) Misses Q1 EPS by 79c, Revenues Beat

Ultragenyx Reports First Quarter 2021 Financial Results and Corporate Update

May 4, 2021 4:01 PM EDT

First quarter 2021 total revenue of $99.4 million and Crysvita1 revenue to Ultragenyx of $42.1 million

2021 Crysvita revenue in Ultragenyx territories1 guidance of $180 million to $190 million reaffirmed

Strong Dojolvi launch continues with approximately 180 patients on reimbursed commercial therapy in the United States

NOVATO, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today reported its financial results for the... More